Neoadjuvant and Concurrent Chemotherapy Have Varied Impacts on the Prognosis of Patients with the Ascending and Descending Types of Nasopharyngeal Carcinoma Treated with Intensity-Modulated Radiotherapy.
Neoadjuvant and Concurrent Chemotherapy Have Varied Impacts on the Prognosis of Patients with the Ascending and Descending Types of Nasopharyngeal Carcinoma Treated with Intensity-Modulated Radiotherapy.
复制标题
新辅助和同步化疗对升型和降型鼻咽癌调强放疗患者的预后有不同的影响
DOI：
10.1371/journal.pone.0161878
复制
发表时间：
2016
期刊：
影响因子：
3.7
通讯作者：
Sun Y
中科院分区：
文献类型：
--
作者：
Yao JJ;Zhou GQ;Zhang F;Zhang WJ;Lin L;Tang LL;Mao YP;Ma J;Sun Y
比较同步放化疗（CCRT）、新辅助化疗（NACT）+调强放疗（RT）或NACT + CCRT治疗上升型（T4、N 0 -1）和下降型（T1- 2、N3）鼻咽癌的疗效。回顾性分析了2009年10月至2012年2月期间在单一机构治疗的839例上升型或下降型NPC患者。236例患者接受了CCRT，302例患者接受了NACT + RT，301例患者接受了NACT + CCRT。4年总生存率、无远处转移生存率、局部无复发生存率、无淋巴结复发生存率、局部无复发生存率和无进展生存率分别为75.2%和73.4%（P = 0.114），85.7%和74.1%上升型和下降型分别为88.8%和97.1%（P = 0.013）、96.9%和94.1%（P = 0.122）、86.9%和91.2%（P = 0.384）、73.7%和66.2%（P = 0.063）。亚组分析显示，与CCRT相比，NACT + RT在上升型中显著提高了无远处转移生存率和无进展生存率，NACT +RT与NACT + CCRT的生存曲线无显著差异。对于下降型，NACT +RT、CCRT和NACT + CCRT组的生存曲线无显著差异，生存获益主要来自CCRT。与NACT + CCRT或CCRT相比，NACT + RT可能是治疗上升型的合理方法。虽然同期化疗对降型患者有效，但NACT + CCRT可能是降型患者更合适的方案。
To compare the outcomes of patients with ascending type (T4&N0-1) and descending type (T1-2&N3) of nasopharyngeal carcinoma (NPC) treated with concurrent chemoradiotherapy (CCRT), neoadjuvant chemotherapy (NACT) + intensity-modulated radiotherapy (RT) or NACT + CCRT. Retrospective analysis of 839 patients with ascending or descending types of NPC treated at a single institution between October 2009 to February 2012. CCRT was delivered to 236 patients, NACT + RT to 302 patients, and NACT + CCRT to 301 patients. The 4-year overall survival rate, distant metastasis-free survival rate, local relapse-free survival rate, nodal relapse-free survival rate, loco-regional relapse-free survival rate, and progression free survival rate were 75.2% and 73.4% (P = 0.114), 85.7% and 74.1% (P = 0.008), 88.8% and 97.1% (P = 0.013), 96.9% and 94.1% (P = 0.122), 86.9% and 91.2% (P = 0.384), 73.7% and 66.2% (P = 0.063) in ascending type and descending type. Subgroup analyses indicated that NACT + RT significantly improved distant metastasis-free survival rate and progression-free survival rate when compared with CCRT in the ascending type, and there were no significant differences between the survival curves of NACT +RT and NACT + CCRT. For descending type, there were no significant differences among the survival curves of NACT +RT, CCRT, and NACT + CCRT groups, and the survival benefit mainly came from CCRT. Compared with NACT + CCRT or CCRT, NACT + RT may be a reasonable approach for ascending type. Although concurrent chemotherapy was effective in descending type, NACT + CCRT may be a more appropriate strategy for descending type.
登录
查看更多内容
DOI：
10.1186/1748-717x-8-265
发表时间：
2013-11-13
期刊：
Radiation oncology (London, England)
影响因子：
--
作者：
Sun X;Zeng L;Chen C;Huang Y;Han F;Xiao W;Liu S;Lu T
通讯作者：
Lu T
影响因子：
45.3
作者：
Hui, Edwin P.;Ma, Brigette B.;Chan, Anthony T.
通讯作者：
Chan, Anthony T.
影响因子：
3.1
作者：
Chen, J. L. -Y.;Huang, Y. -S.;Wang, C. -W.
通讯作者：
Wang, C. -W.
影响因子：
45.3
作者：
Ma, J;Mai, HQ;Mo, HY
通讯作者：
Mo, HY
DOI：
10.1016/j.ijrobp.2004.03.002
发表时间：
2004-09-01
影响因子：
7
作者：
Lin, JC;Liang, WM;Lin, AC
通讯作者：
Lin, AC